Preferred Label : avapritinib;

MeSH Hyperonym : 5-Pyrimidinemethanamine, alpha-(4-fluorophenyl)-alpha-methyl-2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-yl)-1-piperazinyl)-, (alphaS)-;

UNII : 513P80B4YJ;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/ayvakyt
2023
false
false
false
France
French
administration, oral
avapritinib
avapritinib
drug information
aggressive systemic mastocytosis
mastocytosis, systemic
Systemic Mastocytosis with an Associated Myeloid Neoplasm
leukemia, mast-cell
adult

---
https://www.has-sante.fr/jcms/p_3359432/fr/ayvakyt-avapritinib-mastocytose-systemique-agressive-asm
https://www.has-sante.fr/jcms/p_3359458/fr/decision-n2022-0278/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ayvakyt
2022
false
false
false
France
adult
Systemic Mastocytosis with an Associated Myeloid Neoplasm
protein kinase inhibitors
avapritinib
leukemia, mast-cell
treatment outcome
insurance, health, reimbursement
guidelines for drug use
continuity of patient care
administration, oral
evaluation of the transparency committee
avapritinib
aggressive systemic mastocytosis
mastocytosis, systemic

---
https://www.has-sante.fr/jcms/p_3376534/fr/ayvakyt-avapritinib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
mastocytosis, systemic
aggressive systemic mastocytosis
adult
Systemic Mastocytosis with an Associated Myeloid Neoplasm
leukemia, mast-cell
administration, oral
avapritinib
evaluation of the transparency committee
avapritinib

---
https://www.has-sante.fr/jcms/p_3242174/fr/ayvakyt
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
avapritinib
guidelines for drug use
gastrointestinal stromal tumors
adult
Metastatic Gastrointestinal Stromal Tumor
neoplasm metastasis
Unresectable Malignant Gastrointestinal Stromal Tumor
mutation
PDGFRA NP_006197.1:p.D842V
PDGFRA Gene Mutation
receptor, platelet-derived growth factor alpha
pyrazoles
pyrroles
triazines
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
avapritinib
avapritinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pyrazoles
pyrazoles
pyrroles
pyrroles
triazines
triazines
antineoplastic agents
antineoplastic agents
gastrointestinal stromal tumors
orphan drug production
neoplasm metastasis
mutation
gastrointestinal stromal tumors
receptor, platelet-derived growth factor alpha
administration, oral
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor
avapritinib
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
PDGFRA NP_006197.1:p.D842V
avapritinib
avapritinib

---
Nous contacter.
07/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.